Download PDF
Der Klinikarzt 2010; 39(10): 456-460
DOI: 10.1055/s-0030-1268527
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Aktuelle medikamentöse Therapie kolorektaler Karzinome – Standards im adjuvanten und im metastasierten Stadium

Update drug therapy of colorectal carcinomas – Standards in the adjuvant and metastasized stageAnnika Siegmund1 , Dirk Jäger1
  • 1Nationales Centrum für Tumorerkrankungen, Abteilung Medizinische Onkologie, Heidelberg
Further Information

Publication History

Publication Date:
02 November 2010 (online)

Also available at
    Permissions and Reprints

In der adjuvanten Situation profitieren Patienten mit einem Kolonkarzinom im Stadium III von einer Kombinationstherapie nach FOLFOX-Protokoll. Bei Kontraindikationen ist auch ein Verzicht auf Oxaliplatin möglich, in diesen Fällen empfiehlt sich aus Gründen der Praktikabilität die Therapie mit dem oralen Fluoropyrimidin Capecitabin. Risikopatienten im Stadium II sollten ebenfalls über die Möglichkeit einer adjuvanten Behandlung aufgeklärt werden.

Im metastasierten Stadium sollte jedem Patienten, sofern keine Kontraindikationen bestehen, alle wirksamen Medikamente (5-FU oder Capecitabin, Oxaliplatin, Irinotecan) angeboten werden. Die individuelle Situation und die Nebenwirkungsprofile der Substanzen sind wichtige Entscheidungshilfen für die Sequenz. Durch die Kombination von Chemotherapie mit Antikörpern (Bevacizumab sowie bei nachgewiesenem KRAS-Wildtyp auch Cetuximab oder Panitumumab) ist statistisch eine weitere Verlängerung des Gesamtüberlebens möglich. Bei Patienten mit begrenzter Metastasierung sollte immer auch die Resektabilität überprüft werden.

Combined therapy according to the FOLFOX protocol is of advantage to Stage III colocarcinoma adjuvant stage patients. In case of a contraindication it is also possible to abstain from oxaliplatin. In such cases it would be practicable to employ the oral fluoropyrimidine capecitabine. Stage II risk patients should also be informed about the possibility of an adjuvant treatment.

Every patient in the metastasized stage should be offered – if there are no contraindications – all the available effective preparations such as 5-FU or capecitabine, oxaliplatin, irinotecan. The choice between these substances is decisively determined by their side effects profile. The total survival rate may be statistically extended still further by combining chemotherapy with antibodies (bevacizumab as well as in case of an established KRAS wild-type also cetuximab or panitumumab). In case of patients with limited metastization, it would always be recommendable to consider the possibility of resection.

Key words

Colorectal carcinoma - medicamental - adjuvant therapy - metastasized stage - chemotherapy - monoclonal antibodies

Literatur

  • 1 Robert Koch-Institut , (Hrsg).. Krebs in Deutschland 2003–2004. Häufigkeiten und Trends. 6. überarbeitete Auflage. Berlin; 2008
    Google Scholar
  • 2 Wittekind C, Meyer HJ. TNM Klassifikation maligner Tumoren. Auflage. Weinheim: Wiley-VCH; 2010. 7
    Google Scholar
  • 3 O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.  J Natl Cancer Inst. 2004;  96 1420-1425
    CrossrefPubMedGoogle Scholar
  • 4 Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.  Clin Colorectal Cancer. 2006;  6 278-287
    CrossrefPubMedGoogle Scholar
  • 5 Andre T, Boni C, Mounedji-Boudiaf L et al.. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.  N Engl J Med. 2004;  350 2343-2351
    CrossrefPubMedGoogle Scholar
  • 6 De Gramont A, Boni C, Navarro M et al.. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years.  J Clin Oncol. 2007;  25 4007
    PubMedGoogle Scholar
  • 7 Wolmark N, Wieand S, Kuebler JP. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07.  J Clin Oncol. 2005;  23
    PubMedGoogle Scholar
  • 8 Bayraktar UD, Bayraktar S, Herna S et al.. Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?.  J Clin Oncol. 2009;  27 4046
    PubMedGoogle Scholar
  • 9 Wolmark, ASCO. 2009
    Google Scholar
  • 10 Sargent DJ, Goldberg RM, Jacobson SD. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 1091-1097
    CrossrefPubMedGoogle Scholar
  • 11 McCleary NA, Meyerhardt J, Green E et al.. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database.  J Clin Oncol. 2009;  27 4010
    PubMedGoogle Scholar
  • 12 Schmiegel W, Reinacher-Schick A, Arnold D et al.. Update S3-guideline „colorectal cancer“ 2008.  Z Gastroenterol. 2008;  46 799-840
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gray R, Barnwel J Quasar Collaborative Group et al.. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.  Lancet. 2007;  370 2020-2029
    CrossrefPubMedGoogle Scholar
  • 14 Kopetz S, Chang GJ, Overman MJ et al.. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.  J Clin Oncol. 2009;  27 3677-3683
    CrossrefPubMedGoogle Scholar
  • 15 Adam R, Wicherts DA, de RJ Haas et al.. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?.  J Clin Oncol. 2009;  27 1829-1835
    CrossrefPubMedGoogle Scholar
  • 16 Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis.  Colorectal Cancer Collaborative Group. BMJ. 2000;  321 531-535
    PubMedGoogle Scholar
  • 17 Saltz LB, Clarke S, Díaz-Rubio E et al.. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.  J Clin Oncol. 2008;  26 2013-2019
    CrossrefPubMedGoogle Scholar
  • 18 Van Cutsem E, Köhne CH, Hitre E et al.. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.  N Engl J Med. 2009;  360 1408-1417
    CrossrefPubMedGoogle Scholar
  • 19 De Gramont A, Figer A, Seymour M et al.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-2947
    PubMedGoogle Scholar
  • 20 Giacchetti S, Perpoint B, Zidani R et al.. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2000;  18 136-147
    PubMedGoogle Scholar
  • 21 Douillard JY, Cunningham D, Roth AD et al.. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.  Lancet. 2000;  355 1041-1047
    CrossrefPubMedGoogle Scholar
  • 22 Köhne CH, van Cutsem E, Wils J et al.. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.  J Clin Oncol. 2005;  23 4856-4865
    CrossrefPubMedGoogle Scholar
  • 23 Tournigand C, Cervantes A, Figer A et al.. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer -- a GERCOR study.  J Clin Oncol. 2006;  24 394-400
    CrossrefPubMedGoogle Scholar
  • 24 Chibaudel B, Maindrault-Goebel F, Lledo G et al.. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.  J Clin Oncol. 2009;  27 5727-5733
    CrossrefPubMedGoogle Scholar
  • 25 Koopman M, Antonini NF, Douma J et al.. Sequential versus combination chemo therapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.  Lancet. 2007;  370 135-142
    CrossrefPubMedGoogle Scholar
  • 26 Seymour MT, Maughan TS, Ledermann JA et al.. Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial.  Lancet. 2007;  370 143-152
    CrossrefPubMedGoogle Scholar
  • 27 Díaz-Rubio E, Tabernero J, Gomez-Espana A et al.. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.  J Clin Oncol. 2007;  25 4224-4230
    CrossrefPubMedGoogle Scholar
  • 28 Porschen R, Arkenau HT, Kubicka S et al.. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.  J Clin Oncol. 2007;  25 4217-4223
    CrossrefPubMedGoogle Scholar
  • 29 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
    CrossrefPubMedGoogle Scholar
  • 30 Amado RG, Wolf M, Peeters M et al.. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1626-1634
    CrossrefPubMedGoogle Scholar
  • 31 Tol J, Koopman M, Cats A et al.. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer.  N Engl J Med. 2009;  360 563-572
    CrossrefPubMedGoogle Scholar
  • 32 Hecht JR, Mitchell E, Chidiac T et al.. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.  J Clin Oncol. 2009;  27 672-680
    CrossrefPubMedGoogle Scholar

Korrespondenz

Prof. Dr. med. Dirk Jäger

Nationales Centrum für Tumorerkrankungen Abteilung Medizinische Onkologie

Im Neuenheimer Feld 350

69120 Heidelberg

Fax: 06221/567225

Email: dirk.jaeger@med.uni-heidelberg.de

      >